The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...
REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and ...
14don MSN
2 beaten-down artificial intelligence (AI) stocks for contrarian investors to consider buying
These aren't for the faint of heart.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results